Japanese Medical Devices Firm Create Medic Plans to Expand India Operations

Why It Matters

Local sales and manufacturing give Create Medic tighter control over pricing, supply chain resilience, and a foothold in one of the fastest‑growing medical‑device markets worldwide.

Key Takeaways

• Create Medic will open sales offices in Chennai, Delhi, Kolkata, Ahmedabad.
• Company targets roughly $12 million annual revenue from India.
• Plans a $12 million manufacturing plant to serve India, Asia, Africa.
• Shifts from distributor model to direct sales in Indian market.
• Local production aims to reduce reliance on imported components amid supply disruptions.

Pulse Analysis

India’s medical‑device sector is on a steep growth trajectory, driven by expanding hospital networks, rising per‑capita income, and a surge in minimally invasive procedures. Silicone catheters, Create Medic’s core product, are in high demand for urology, gastroenterology and PEG care. By establishing a sales presence in four major metros, the company can engage directly with leading institutions such as Tata Memorial Hospital and Apollo Proton Cancer Centre, accelerating market penetration and brand visibility.

The decision to build a $12 million manufacturing plant marks a strategic pivot from reliance on overseas factories in Vietnam, China and Japan to a localized supply chain. Direct sales reduce distributor margins, while domestic production shortens lead times and mitigates currency and tariff risks. Moreover, the plant is positioned as a regional hub, allowing Create Medic to export to nearby Asian economies and even Africa, leveraging India’s trade agreements and lower logistics costs.

Supply‑chain disruptions linked to geopolitical tensions in West Asia have highlighted the fragility of imported components. By sourcing more inputs locally, Create Medic can safeguard its production schedule and maintain price stability for Indian hospitals. The expansion also intensifies competition among global device makers vying for market share in a lucrative yet price‑sensitive environment, prompting further investment in innovation and cost‑effective solutions. If the revenue target is met, the Indian operation could become a cornerstone of the firm’s global growth strategy.